CD8A and neoplasm: To further evaluate the impact of the different treatments on the immune population landscape, we calculated the ratios of MDSCs (both PMN-MDSCs and M-MDSCs) to CD8+T and NK cells in blood, spleen, lungs, and tumors from the mice in the therapeutic groups and contrasted the results with data obtained from age-matched tumor-free mice.